SightfileU.S. market data from official filings

Companies › PTGX

PROTAGONIST THERAPEUTICS (PTGX)

Institutional ownership, SEC filings and insider activity

Sector: Healthcare & Pharma · SEC CIK 0001377121 · EDGAR filings · Updated 2026-06-25

PROTAGONIST THERAPEUTICS (PTGX) has reported institutional ownership of 122.4%, with 317 institutional managers holding positions valued at $8.30B per the latest 13F reporting period. SEC filings include an active notice of delisting or failure to satisfy a continued listing rule (8-K Item 3.01).

Institutional ownership
122.4%
Institutional managers
317
Reported 13F value
$8.30B
Insider activity
68 trans.
−$35.9M net selling
Data flags
1 active
from SEC filings

Latest updates

Institutional ownership overview

According to SEC 13F filings tracked by Sightfile, PROTAGONIST THERAPEUTICS has 317 institutional holders and institutional ownership of 122.4%.

Insider activity

Insiders reported 68 transactions (0 buys, 31 sells) across 8 reporting insiders, with a net reported value of −$35.9M.

Data flags from SEC filings

Active notice of delisting or failure to satisfy a continued listing rule (8-K Item 3.01), most recently filed 2023-07-03 (recurring since 2023-07-03) — source filing. The authoritative details are those stated in the filing itself.

Related companies

BAXTER INTL INC (BAX) · ICON PLC (ICLR) · SOLVENTUM CORP (SOLV) · KYMERA THERAPEUTICS (KYMR) · HALOZYME THERAPEUTICS INC (HALO) · REPLIGEN CORP COM (RGEN)

See full history, cross-references and alerts on Sightfile
Sightfile provides information only — not investment advice, recommendations, or an assessment of any security. Data is derived from official public sources (SEC EDGAR and U.S. government agencies), may contain errors or delays, and should be verified against the source filing before relying on it.
Data sources: SEC EDGAR (filings, 13F, FTD), aggregated by Sightfile. Page updated 2026-06-25.